Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (22566)	1/18/2007 1:33:35 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

In theory of course a use patent is available for new ideas for an old drug. But that is often a very slender reed to base a business on - there have been few successful examples I can think of where a use patent was the only protection for a new use of an existing marketed drug. One was CollaGenex with low-dose doxycycline - but there they had some added protection for a while because there was no generic with the approved dose. But some generic eventually launched against them anyhow. Nitrobid is another example of a failure, although there it is unclear whether doctors are in fact prescribing the generic components separately. Peter